UNSPSC 51271705: Amolanone hydrochloride

This classification denotes an anesthetic agent with the molecular formula C20H23NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M36927R46E, chemically known as 2(3h)-benzofuranone, 3-(2-(diethylamino)ethyl)-3-phenyl-, hydrochloride but more generally known as amolanone hydrochloride, which bears US NIH Compound Identifier 22336. Most nations, for tariff and trade purposes, schedule amolanone hydrochloride under HS 29322985. As of Q4 2014, AMOLANONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Amolanone hydrochloride bears US NLM identifiers UMLS ID C2698096 and NCI Concept Code C75084. SMILES: CCN(CC)CCC1(C2CCCCC2OC1=O)C3CCCCC3.CL.

UNSPSC 51271705 Amolanone hydrochloride is a Commodity code representing active pharmaceutical ingredients and finished-form drugs procured by state and local health systems, correctional facilities, and other government-administered healthcare operations. State and local governments buy under this code as part of broader pharmaceutical supply agreements that bundle generic drugs, over-the-counter products, and specialty medications sourced through authorized wholesaler networks. The work involves manufacturer capacity, pricing, regulatory compliance (FDA approval, cGMP certification, Drug Supply Chain Security Act adherence), and logistics management including inventory turnover, expiration dating, and chargeback processing. Issuing bodies include state health departments and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions and health systems to negotiate volume pricing and standardized supply terms.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota, Oregon, and other member states. The solicitation calls for manufacturers to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded vendors selected to take effect July 1, 2026. Evaluation weights price competitiveness at 75 percent; vendors must demonstrate EDI capability, maintain relationships with at least two of the three wholesalers with chargeback systems, carry $2 million in network security and privacy liability insurance, and agree to a 3 percent administrative fee. The contract term runs two years for new vendors with optional extensions, while incumbents' amendments extend through June 30, 2028. No specific dollar values or set-aside designations were disclosed in the solicitation materials.